title: Pharmaceutical policy reform in the Russian Federation.
abstract: Of Russia's 142 million citizens, fewer than 20 million are enrolled in outpatient drug coverage plans. The current government aims to establish universal health insurance including outpatient medicines. Based on the current political and regulatory environment, this report explores pharmaceutical pricing options for Russia that balance greater access to medicines with achieving government plans of boosting local pharmaceutical production. To match innovative medicine prices with their health benefits, in the long run, we suggest that Russia consider adopting value-based pricing, and in the short term, that it introduce direct price negotiations and price drugs according to reference countries that use health technology assessment. Although generic market shares are high, generic medicine prices are higher than they should be. We propose tenders at the manufacturer level for the pricing of high-selling generics, and free pricing for products with sufficient market competition. These policy recommendations are a jumping-off point for further discussion about how pharmaceutical policy could aid this major economy to achieve its population health and health service goals.
authors.affiliation: London School of Economics and Political Science.
authors.forename: Caroline
authors.initials: C
authors.lastname: Rudisill
authors.affiliation: King's College London.
authors.forename: Sotiris
authors.initials: S
authors.lastname: Vandoros
authors.affiliation: University of Chicago.
authors.forename: Joseph George
authors.initials: JG
authors.lastname: Antoun
mesh_terms: D003365:Costs and Cost Analysis; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D006291:Health Policy; D006801:Humans; D012426:Russia